Stock AnalizProgyny, Inc. PGNY
Misc Health and Biotechnology Services · IPO 2019 · data as of November 13, 2026
Progyny, Inc. (PGNY) is a healthcare company listed in the US with a market value of about $2.7B. In the twelve months to September 30, 2026 it had revenue of $1.3B and net income of $91M, a net margin of 6.8%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (2/5).
Key numbers: a P/E of 33.2, a price to free cash flow of 14.8, 5-year revenue growth of 30% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 20% above the current price.
Score: 2.8 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $1.2B | $1.1B | $787M | $501M | $345M | $230M | $105M | $49M |
| Net income | $91M | $59M | $54M | $62M | $30M | $66M | $46M | -$9M | $661000 | -$12M |
| Free cash flow | $180M | $192M | $174M | $185M | $77M | $24M | $35M | -$4M | $2M | -$10M |
| EPS (diluted) | $1.09 | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 | $0.47 | $-0.41 | $0.04 | $-2.37 |
| Net margin | 6.8% | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% | -3.7% | 0.6% | -25.6% |
| ROIC | — | 9.6% | 10.0% | 9.5% | 4.8% | 9.8% | 3.7% | 6.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $37.25, 3% above the current price; targets range from $35.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $2.11 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Progyny’s P/E ratio?
About 33.2, based on the last twelve months of diluted earnings per share (forward P/E about 15.6).
Is Progyny stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 20% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Progyny pay a dividend?
Not currently.
Is Progyny a good stock to buy?
We do not give buy or sell advice. Progyny scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.